Turning Point Therapeutics Inc

+0.05 (+0.07%)
Accounting Issues/SEC Inquiries, Mergers / Acquisitions

Bristol Myers Squibb To Acquire Turning Point Therapeutics For $4.1 Bln

Published: 06/03/2022 11:27 GMT
Turning Point Therapeutics Inc (TPTX) - Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company.
Bristol-myers Squibb Co - Deal for $76.00 per Share.
Bristol-myers Squibb Co - Deal Expected to Be Accretive to Non-GAAP Earnings per Share Beginning in 2025.
Bristol-myers Squibb Co- Expects to Finance Acquisition With Cash on Hand.
Bristol-myers Squibb Co - All-cash Transaction for a Total Consideration of $4.1 Billion in Equity Value.
Bristol-myers Squibb - Deal Expected to Be Up to $0.08 per Share Dilutive to Non-GAAP EPS in 2022 Prior to Any Impact From an Acquired In-process Research and Development Charge.
Bristol-myers Squibb - Turning Point Therapeutics' Board Unanimously Recommends That Shareholders Tender Their Shares in Tender Offer.
Bristol-myers Squibb - Accounting Treatment As a Business Combination Or Asset Acquisition Will Be Determined Upon Expected Close of Deal in Q3.